Brief: Redhill Biopharma's Positive Opaganib Results Indicate Reduction In Venetoclax Resistant Cells
15/12/2025 12:18
Dec 15 (Reuters) - Redhill Biopharma Ltd 2RHy.F: REDHILL BIOPHARMA'S POSITIVE OPAGANIB RESULTS INDICATE REDUCTION IN VENETOCLAX RESISTANT CELLS REDHILL BIOPHARMA: IN VIVO RESULTS INDICATE OPAGANIB WITH VENETOCLAX REDUCES CHRONIC LYMPHOCYTIC LEUKEMIA CELLS BY HALF COMPARED TO CONTROLS Source text: ID:nPn1Pp5Lka Further company coverage: [2RHy.F] ((Reuters.Briefs@thomsonreuters.com;))